Morgan Stanley Upgrades Qiagen N.V. to 'Buy'
Morgan Stanley raised Qiagen's rating to 'buy' with a $42 price target, a 7.86% upside from the current price.
Key Points
- Morgan Stanley analyst Steve Beuchaw upgraded Qiagen N.V. to 'buy' with a $42 price target on June 23, 2026.
- Morgan Stanley's $42 price target implies 7.86% upside from Qiagen N.V.'s ($QGEN) current $38.94 share price.
- Qiagen shares traded near $38.73 on Friday, with a market cap of $8.03 billion and a P/E ratio of 19.87.
- Institutional activity saw Wellington Management increase its stake by 933,394 shares, while Deutsche Bank reduced its holdings by 1,910,454 shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Morgan Stanley has upgraded its rating on Qiagen N.V. (NYSE:QGEN) to 'buy' with a new price target of $42. The upgrade, announced on June 23, 2026, comes as analyst Steve Beuchaw sees potential upside for the company's stock.
Morgan Stanley vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Qiagen N.V.
Several institutional investors have adjusted their positions in Qiagen. Wellington Management Group added 933,394 shares, bringing its total to 14,364,303 shares valued at approximately $575.1 million, marking a 6.9% increase. Price T Rowe Associates also increased its stake by 421,381 shares to 8,429,334 shares worth around $337.5 million, a 5.3% rise. Vanguard Capital Management opened a new position with 6,106,275 shares valued at about $247.4 million. Meanwhile, Deutsche Bank reduced its holdings by 1,910,454 shares to 5,601,957 shares, a decrease of 25.4%. BlackRock added 117,495 shares, now holding 5,250,461 shares valued at $210.2 million.
Qiagen N.V. Stock Down 9.7%
Shares of Qiagen N.V. traded near $38.73 on Friday. The company has a market cap of $8.03 billion and a P/E ratio of 19.87. Its 52-week range is between $32.53 and $57.82, with a 50-day moving average of $36.30 and a 200-day moving average of $43.78. Qiagen has a beta of 0.658, indicating lower volatility compared to the market. The company maintains a solid balance sheet with a current ratio of 3.215 and a quick ratio of 2.207.
$QGEN price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Qiagen reported revenue of approximately $2.10 billion, reflecting a growth rate of 1.8%. The company achieved a net margin of 19.16% and a return on equity of 11.93%. Earnings per share stood at $1.96. Qiagen is expected to release its next earnings report on May 6, 2026.
Dividend
Qiagen pays an annual dividend of $0.35 per share, yielding about 0.9%. The company's dividend payout ratio is 13.41%, indicating a conservative approach to shareholder returns.
Insider Buying and Selling at Qiagen N.V.
Recent insider activity at Qiagen includes several sales. On August 15, 2025, Roland Sackers sold 31,423 shares at an average price of $49.21, while Thierry Bernard sold 25,000 shares at $48.80. Additionally, on August 14, 2025, Roland Sackers sold another 18,577 shares at $49.00.
Analysts Set New Price Targets
Morgan Stanley upgraded Qiagen to 'buy' with a $42 price target on June 23, 2026. Stifel and TD Cowen both maintained their 'hold' ratings with targets of $36 and $40, respectively, in May 2026. JP Morgan maintained a 'buy' rating with a $45 target, while Citigroup and Barclays held 'hold' ratings with $38 targets. The analyst consensus is a 'buy' with an average target price of $43.96 from 14 analysts.
About Qiagen N.V.
Qiagen N.V. is a global provider of molecular diagnostics and research solutions, headquartered in Venlo, Netherlands. The company specializes in transforming biological samples into molecular insights, offering a range of products from sample technologies to bioinformatics solutions. With approximately 5,500 employees, Qiagen serves sectors including molecular diagnostics and life sciences. Thierry L. Bernard serves as the company's CEO.
Bottom Line
Morgan Stanley's upgrade to 'buy' reflects confidence in Qiagen's potential, with a new price target set at $42. Investors keep a close eye on such ratings as they can influence stock performance. It's important to note that these analyst opinions are based on available data and market conditions as of June 23, 2026.
Get Qiagen N.V. alerts
New 13F filings, insider trades, and analyst moves on $QGEN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.